MiNK Therapeutics will announce Q1 2025 financial results on May 15, followed by a conference call at 8:30 a.m. ET. MiNK Therapeutics, Inc. announced that it will release its first quarter 2025 ...

MiNK Therapeutics, Inc. announced its first-quarter 2025 financial results and highlighted significant progress in its development of allogeneic invariant natural killer T (iNKT) cell therapies. The ...

Good morning, and welcome to MiNK Therapeutics' Fourth Quarter and Full Year 2022 Conference Call and Webcast. All participants will be in a listen-only mode until the question-and-answer session.

Thank you for standing by. I would like to welcome everyone to the MiNK Therapeutics Third Quarter 2024 Financial Results. I would now like to turn the call over to Alexa Buffa from MiNK's Corporate ...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2025 Earnings Call Transcript May 15, 2025 Operator: Thank you for standing by. My name is Rochelle, and I will be your conference operator today. At this time ...

Operating Cash Burn-- Reduced Q2 operating cash burn by over 30% year-over-year, reflecting operational efficiencies. Cash Balance-- $1.7 million cash balance at Q2 2025 quarter end, plus an ...

Emily Bodnar – H.C. Wainwright: Operator: Thank you for standing by. I would like to welcome everyone to the MiNK Therapeutics Third Quarter 2024 Financial Results. I would now like to turn the call ...

MiNK Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.06 EPS, expectations were $-0.55. Operator: Good morning, and welcome to MiNK Therapeutics’ Second Quarter 2025 Conference ...